Guardant Health, Inc., a leader in precision oncology, today announced an agreement with Illumina Inc., a global leader in DNA sequencing and chip-based technologies, helps resolve their ongoing litigation and drive joint resolution to foster long-term business partnerships. length of companies. The three-year agreement includes a joint request to dismiss […]
Featured News
Medisca is expanding strategic partnerships to improve patient access to much-needed medicines
Medisca has announced the expansion of a network of strategic partnerships designed to secure and stabilize global access to high quality active pharmaceutical ingredients (APIs) for the manufacture of important drugs. The start of this mission marks USP Exclusive Thyroid Partners in 2021, which has now expanded to Progesterone USP […]
Astellas Completes Acquisition of Iveric Bio
Astellas Pharma Inc. announced that it has successfully completed the acquisition of IVERIC bio, Inc. with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has […]
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Gilead Science Inc, announced its largest commitment to health equity for Indigenous Australian and Canadian communities. This initiative will support programs to remove social barriers to care that continue to contribute to HIV and viral hepatitis transmission in Indigenous communities. Gilead is in talks with two Indigenous-led organizations, the Lowitja […]
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Genmab A/S today announced that the European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP) has adopted a positive opinion proposing a conditional marketing authorization for ecoritamab as monotherapy in the treatment of adult patients with relapsed or refractory dual- or multiple-lineage systemic B-cell lymphoma (DLBCL). The European Commission’s […]
Establishment Labs Celebrates Opening of Sulàyöm Innovation Campus and Outlines New and Expanded Capabilities
Establishment Labs Holdings Inc., a global health technology company dedicated to improving women’s health and well-being, primarily in breast aesthetics and reconstruction, today announced the opening of its facility at Sulayöm innovation in the Coyol Free Zone, Costa Rica. The Sulayöm campus will support the continued growth of Established Laboratories […]
Nutex health hospitals win six new outstanding awards
Nutex Health Inc., a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that six Nutex hospitals have won notable awards this quarter. Each award was voted on by their respective communities, as a reflection of […]
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
Genentech, a member of the Roche Group , announced that the OCARINA II phase III trial evaluating Ocrevus® (ocrelizumab) as a 10-minute subcutaneous injection twice a year met the primary and secondary endpoints in patients with the Relapsing MS or primary progressive MS (RMS or PPMS). Subcutaneous Ocrevus was found […]
Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Incyte announced the positive review results from the pivotal study TRuE-AD3, randomized, vehicle-controlled, evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children ( ages 2 to < 12 years old) with atopic dermatitis. The study met the primary endpoint and showed more patients treated with ruxolitinib cream 0.75% […]
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
Sensorion, a pioneering clinical-stage biotech company dedicated to the development of new therapies to restore, treat, and prevent hearing loss disorders, today announced that it has submitted an Application Initial clinical trial (CTA) for OTOF-GT for the UK Medicines and Health Agency. The Healthcare Products Regulatory Authority (MHRA). The Phase […]
